IFNB1 and myeloid sarcoma: We intensively studied surface molecules on peripheral blood (PB) T cells from fingolimod-treated MS (F-MS) patients, interferon (IFN)-β-treated patient, patients not treated with disease modifying dugs (DMD) and healthy subjects (HS) (Table 1).